NRIX
Nurix Therapeutics, Inc.
NRIX's fundamentals are strong: revenue more than tripled and its operating margin went from −319% to 41%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NRIX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NRIX's revenue, profitability, cash flow and balance sheet are all currently strong.
NRIX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.7x | $15.49 | -0.7% |
| Current | 6.8x | $15.60 | — |
| Fair | 11x | $24.25 | +55% |
| Expensive | 11x | $25.81 | +65% |
Historical ranges are pointers, not guarantees.
NRIX's PE is 6.8x, but its earnings don't support one, so it isn't a reliable read right now.
NRIX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NRIX's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NRIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.30 | +$5.26 |
| Q2 2026 | -$3.46 | -$0.86 |
| Q1 2026 | -$3.17 | -$0.38 |
| Q4 2025 | -$3.05 | -$0.17 |
| Q3 2025 | -$2.96 | -$0.05 |
| Q2 2025 | -$2.60 | +$0.32 |
| Q1 2025 | -$2.79 | -$0.13 |
| Q4 2024 | -$2.88 | -$0.23 |
NRIX has returned to profit: it earned $2.30 per share over the past year, after losing money the year before.
NRIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $673.1M | +8426% |
| Q2 2026 | $9M | -79% |
| Q1 2026 | $6.3M | -66% |
| Q4 2025 | $13.6M | +2.2% |
| Q3 2025 | $7.9M | -37% |
| Q2 2025 | $44.1M | +264% |
| Q1 2025 | $18.5M | +11% |
| Q4 2024 | $13.3M | -12% |
NRIX's revenue is growing: $673M last quarter, up 8426% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 83% | +1241 points |
| Q2 2026 | -1042% | -932 points |
| Q1 2026 | -1479% | -1139 points |
| Q4 2025 | -612% | -125 points |
| Q3 2025 | -1158% | -724 points |
| Q2 2025 | -110% | +292 points |
| Q1 2025 | -341% | -68 points |
| Q4 2024 | -487% | -188 points |
NRIX's operating margin was 83% last quarter, up 1241 points from the same quarter a year ago, near the top of its range since 2019.
NRIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $614.2M | +$674.3M |
| Q2 2026 | -$98.5M | -$32.7M |
| Q1 2026 | -$73M | -$8.4M |
| Q4 2025 | -$73M | -$22.1M |
| Q3 2025 | -$60.1M | -$15.6M |
| Q2 2025 | -$65.8M | -$24.2M |
| Q1 2025 | -$64.6M | -$19.7M |
| Q4 2024 | -$50.9M | -311% |
NRIX's free cash flow has turned positive after six years mostly in the red: $370M over the past year.
NRIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.6% | +5.1M shares |
| 1 year | +38% | +32M shares |
| 3 years | +114% | +61.8M shares |
| 5 years | +162% | +71.8M shares |
| Available history | +459% | +95.4M shares |
NRIX has 116M diluted shares, up 38% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | $1,000 |
| Q4 2019 | — |
NRIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.4x | Net Cash |
NRIX has more cash than debt.
NRIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 29.8 | Neutral |
NRIX's weekly RSI is 36 (neutral) and its Stochastic is 30 (neutral).
NRIX PE vs Healthcare Sector
NRIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.0 | 29% below |
| 20 week MA | $23.7 | 34% below |
| 50 week MA | $19.7 | 21% below |
| 100 week MA | $16.3 | 4.4% below |
| 200 week MA | $14.9 | 4.5% above |
NRIX has fallen below most of its moving averages, though it's still 4.5% above its 200-week average.
NRIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.0 | $43.8 | +131% |
| 2021 | $43.8 | $30.5 | -30% |
| 2022 | $30.5 | $10.4 | -66% |
| 2023 | $10.4 | $10.3 | -0.6% |
| 2024 | $10.3 | $19.1 | +85% |
| 2025 | $19.1 | $19.3 | +1% |
| 2026 YTD | $19.3 | $15.6 | -19% |
NRIX's yearly returns have swung widely, from +131% in 2020 to −66% in 2022. It's down 19% so far in 2026.